Polycystic Ovary Syndrome (PCOS) Clinical Trial
Official title:
A Phase II, Randomised, Multi-centric, Multi-national Clinical Trial to Evaluate the Efficacy, Tolerability, and Safety of a Fixed Dose Combination of Spironolactone, Pioglitazone & Metformin (SPIOMET) for Adolescent Girls and Young Adult Women (AYAs) With Polycystic Ovary Syndrome (PCOS)
This is a multi-centre, multi-national, double-blinded, placebo-controlled, parallel, randomised Phase II clinical trial to evaluate the efficacy, tolerability, and safety of a fixed dose combination of Spironolactone, Pioglitazone and Metformin (SPIOMET) for adolescent girls and young adult women with polycystic ovary syndrome. Study description: Currently, there is no European Medicines Agency /U.S. Food and Drug Administration (FDA)-approved therapy for polycystic ovary syndrome in adolescent girls and young adult women. Oral contraceptives (OCs) are prescribed off-label to approximately 98% of AYAs with PCOS, including those without pregnancy risk. OCs alleviate key symptoms by inducing a pharmacological combination of anovulatory subfertility, regular pseudo-menses, and extreme elevations of sex hormone-binding globulin (SHBG), but OCs do not revert the underlying pathophysiology, and patients remain at risk for post-treatment subfertility and possibly, for lifelong co-morbidities. Given the key role of hepato-visceral fat excess in the pathogenesis of PCOS, the prime aim of the treatment should be to achieve a preferential loss of central fat, which should in turn normalise the entire PCOS phenotype. Recent evidence disclosed that a treatment consisting of a fixed low-dose combination of two insulin sensitisers [pioglitazone (PIO) and metformin (MET), with different modes of action], and one mixed anti-androgen and anti-mineralocorticoid (spironolactone), was superior to an OC in normalising the PCOS phenotype, including ovulation rates and hepato-visceral fat. The study's main goals are to assess the efficacy, tolerability and safety of a new treatment (SPIOMET) for adolescent girls and young adult women with polycistic ovarian syndrome; the comparison (in this order) of each SPIOMET, spironolactone and pioglitazone (SPIO) and PIO over placebo; and in addition, the comparison of SPIOMET over PIO and over SPIO (in this order). Primary Objective: To test the efficacy of SPIOMET in normalising ovulation rate in adolescents and young adult women with PCOS. Secondary Objectives: To test the efficacy of SPIOMET in normalising the endocrine-metabolic status, to describe the drug safety profile and to assess the adherence and subjective acceptability, as well as the quality of life of the participating subjects.
This is a multi-centre, multi-national, double-blinded, placebo-controlled, parallel, randomised Phase II clinical trial to evaluate the efficacy, tolerability, and safety of a fixed dose combination of Spironolactone, Pioglitazone and Metformin (SPIOMET) for adolescent girls and young adult women (AYAs) with polycystic ovary syndrome (PCOS). Study description: Currently, there is no European Medicines Agency (EMA)/U.S. Food and Drug Administration (FDA)-approved therapy for PCOS in AYAs. Oral contraceptives (OCs) are prescribed off-label to approximately 98% of AYAs with PCOS, including those without pregnancy risk. OCs alleviate key symptoms by inducing a pharmacological combination of anovulatory subfertility, regular pseudo-menses, and extreme elevations of sex hormone-binding globulin (SHBG), but OCs do not revert the underlying pathophysiology, and patients remain at risk for post-treatment subfertility and possibly, for lifelong co-morbidities. Given the key role of hepato-visceral fat excess in the pathogenesis of PCOS, the prime aim of the treatment should be to achieve a preferential loss of central fat, which should in turn normalise the entire PCOS phenotype. Recent evidence disclosed that a treatment consisting of a fixed low-dose combination of two insulin sensitisers [pioglitazone (PIO) and metformin (MET), with different modes of action], and one mixed anti-androgen and anti-mineralocorticoid (spironolactone), was superior to an OC in normalising the PCOS phenotype, including ovulation rates and hepato-visceral fat. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06306417 -
A Randomized Controlled Trial of Acupuncture for Insulin Resistance in Patients With Polycystic Ovary Syndrome
|
N/A | |
Completed |
NCT01927471 -
Nutritional and Metabolic Correlates of Ovarian Morphology in Women With Polycystic Ovary Syndrome
|
||
Completed |
NCT01927432 -
Ultrasound Characterization of Ovarian Follicle Dynamics in Women With Amenorrhea
|
||
Completed |
NCT00805207 -
Sex Steroids, Sleep, and Metabolic Dysfunction in Women
|
N/A | |
Completed |
NCT01999686 -
PCOS Treatment Using DLBS3233, Metformin, and Combination of Both
|
Phase 3 | |
Completed |
NCT03414957 -
Malay Women With PCOS and Their Association With Metabolic Syndrome
|
||
Recruiting |
NCT06143527 -
Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cells for PCOS
|
Phase 1 | |
Completed |
NCT01233206 -
Metformin in High Responder Polycystic Ovary Syndrome (PCOS) Patients Undergoing IVF Cycles
|
Phase 4 | |
Not yet recruiting |
NCT05272657 -
Low-Carb Versus Mediterranean Diet in PCOS
|
N/A | |
Completed |
NCT01733459 -
Efficacy and Safety of DLBS3233 in Subjects With Polycystic Ovary Syndrome (PCOS)
|
Phase 3 | |
Completed |
NCT04264832 -
Body Fat Distribution and Its Associated Factors in Chinese Women With Polycystic Ovary Syndrome
|
||
Completed |
NCT03547453 -
Ovarian Ultrasonography for the Clinical Evaluation of Polycystic Ovary Syndrome
|
||
Terminated |
NCT02865915 -
MLE4901 vs. Placebo for the Treatment of PCOS
|
Phase 2 | |
Completed |
NCT02429128 -
14 Weeks Exercise Training on Lean Women With and Without PCOS
|
N/A | |
Completed |
NCT01899001 -
Mood and Nutrition Interventions in Polycystic Ovary Syndrome
|
N/A | |
Completed |
NCT03151005 -
The Effect of GLP-1 Agonists Versus OCs on Reproductive Disorders and Cardiovascular Risks in Overweight PCOS
|
Phase 4 | |
Completed |
NCT03792282 -
Time-Restricted Feeding(TRF) on Overweight/Obese Women With Polycystic Ovarian Syndrome (PCOS)
|
N/A | |
Completed |
NCT04852510 -
Amelioration of Polycystic Ovary Syndrome Related Disorders by Supplementation of Thymoquinone and Metformin
|
Phase 2/Phase 3 | |
Recruiting |
NCT05200793 -
Efficacy of Empagliflozin or Linagliptin as an Alternative to Metformin for Treatment of Polycystic Ovary Syndrome
|
Phase 4 | |
Not yet recruiting |
NCT01720459 -
Effects of Micronized Trans-resveratrol Treatment on Polycystic Ovary Syndrome (PCOS) Patients
|
N/A |